SecBot SecBot
6-K ·Filed May 26, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001654954-26-005309
Notable filing: 6-K
Actionable Insight ▲ Bullish

This FDA approval is a major catalyst for Datroway, expanding its label to a high-need first-line TNBC population with strong OS data. Monitor upcoming regulatory decisions in EU, China, and Japan under Project Orbis, and watch for confirmatory trial results for the NSCLC accelerated approval. The approval strengthens AstraZeneca's oncology ADC franchise alongside Enhertu.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$187.11
T+0 close · May 26, 2026 · via day close
Latest settled
−11.91%
T+60 · $164.83
Vs SPY
−14.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $187.11entry
  2. T+1 · 6mo ago −0.80%α −0.81% · $185.62
  3. T+5 · 6mo ago −5.19%α −6.41% · $177.39
  4. T+20 · 5mo ago −3.25%α −0.99% · $181.02
  5. T+60 · 3mo ago −11.91%α −14.37% · $164.83

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca and Daiichi Sankyo announced FDA approval of Datroway (datopotamab deruxtecan) as the first TROP2-directed antibody drug conjugate for first-line treatment of metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval is based on the TROPION-Breast02 Phase III trial, which showed a 5.0-month median overall survival improvement (HR 0.79) and a 43% reduction in risk of disease progression or death versus chemotherapy. This expands Datroway's US label to three indications and addresses a significant unmet need for approximately 70% of metastatic TNBC patients who previously had only chemotherapy as a first-line option.

Key Facts

  • FDA approved Datroway for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients not candidates for PD-1/PD-L1 inhibitor therapy.
  • Approval based on TROPION-Breast02 Phase III trial: 5.0-month median OS improvement (HR 0.79; 95% CI 0.64-0.98; p=0.0290), 43% reduction in risk of progression or death (HR 0.57; 95% CI 0.47-0.69; p<0.0001).
  • Objective response rate was 64% for Datroway vs 30% for chemotherapy.
  • Datroway is now approved for three US indications: HR+/HER2- breast cancer, EGFR-mutated NSCLC (accelerated approval), and first-line metastatic TNBC.
  • NCCN Guidelines include Datroway as a Category 1 Preferred first-line treatment option for this patient population.
  • Approximately 11,000 patients with TNBC receive first-line treatment annually in the US; ~70% are not candidates for immunotherapy.

Financial Impact

Datroway addresses a ~11,000 patient annual US addressable population in first-line TNBC, with potential to become standard of care. Combined with existing HR+/HER2- breast cancer and NSCLC approvals, peak sales could be significant, though no specific revenue guidance was provided in the filing.

revenuepipeline value

Risk Factors

  • Competition from other TROP2-directed ADCs (e.g., Gilead's Trodelvy) and emerging therapies in TNBC.
  • Continued approval for the NSCLC indication is contingent on confirmatory trial verification.
  • Pricing and reimbursement dynamics could limit commercial uptake.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005309
Document: 0001654954-26-005309-index-headers.html0001654954-26-005309
Document: 0001654954-26-005309-index.html0001654954-26-005309
Document: 0001654954-26-005309.txt0001654954-26-005309

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026